West Pharmaceutical Services, Inc. (NYSE:WST) Q2 2024 Earnings Conference Call July 25, 2024 9:00 AM ET
Company Participants
John Sweeney - Head of IR
Eric Green - CEO
Bernard Birkett - SVP, Chief Financial and Operations Officer
Conference Call Participants
Paul Knight - KeyBanc Capital Markets
Larry Solow - CJS Securities
Justin Bowers - Deutsche Bank
Mike Ryskin - Bank of America
Matt Larew - William Blair & Company
Jacob Johnson - Stephens
Dan Leonard - UBS
David Windley - Jefferies
Tom DeBourcy - Nephron Research
John Sweeney
Good morning, and welcome to West's Second Quarter 2024 Conference Call. By way of introduction, this is John Sweeney, the new Head of Investor Relations at West. I'm delighted to be here and I look forward to working with all of you.
We issued our financial results earlier this morning, and the release has been posted to the Investors section on the company's website located at westpharma.com. On the call today, we will review our financial results, provide an update on our business, and present an updated financial outlook for the full-year 2024. There is a slide presentation that accompanies today's call and a copy of the presentation is available on the Investors' section of our website.
On Slide 4 is our Safe-Harbor statements. Statements made by management on this call and the accompanying presentation contain forward-looking statements within the meaning of the U.S. Federal Securities Laws. These statements are based on our beliefs and assumptions, current expectations, estimates and forecasts. The company's future results are influenced by many factors beyond the control of the company. Actual results could differ materially from past results as well as those expressed or implied in any forward-looking statements made here.
Please refer to today's press release as well as any other disclosures made by the company regarding the risks to which it is subject, including our 10-K, 10-Q and 8-K reports. During today's call, management will make reference to our non-GAAP financial measures, including organic sales growth, adjusted operating profit, adjusted operating profit margin, and adjusted diluted EPS. Reconciliations and limitations of the non-GAAP financial measures to the comparable financial results prepared in conformity to GAAP are provided in this morning's earnings release.
I'll now turn the call over to our CEO, Eric Green.
Eric Green
Thank you, John, and welcome to West. And I would like to thank Quintin Lai for his partnership over the past eight years and for his many contributions at West.